Zobrazeno 1 - 10
of 72
pro vyhledávání: '"Florian Moik"'
Autor:
Matthias Preusser, Erika Richtig, Florian Moik, Cihan Ay, Martin Pichler, Florian Posch, Armin Gerger, Lukas Koch, Thomas Bauernhofer, Thomas Winder, Dominik A Barth, Sarah Steinlechner, Marie-Christina Mayer, Amelie M Sandner, Franziska Berton, Verena Schlintl, Nikolaus John, Robert Wurm, Patrick Reimann, Christoph Wohlkönig, Philipp J Jost, Angelika Terbuch, Jakob Michael Riedl
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss 12 (2023)
Background C reactive protein (CRP) kinetics have recently been suggested as predictive biomarkers for the efficacy of immune checkpoint inhibitor (ICI) therapy in selected cancer types. The aim of this study was to characterize early CRP kinetics as
Externí odkaz:
https://doaj.org/article/a40a1d9c33b346768e290b28474e9d93
Autor:
Cornelia Englisch, Florian Moik, Johannes Thaler, Silvia Koder, Nigel Mackman, Matthias Preusser, Ingrid Pabinger, Cihan Ay
Publikováno v:
Haematologica, Vol 109, Iss 4 (2023)
Venous thromboembolism (VTE) is a common complication in patients with cancer. Data on the role of natural inhibitors of coagulation for occurrence of cancer-associated VTE are limited, thus, we investigated the association of tissue factor pathway i
Externí odkaz:
https://doaj.org/article/70622f744d904a23ac4e6d653ee1fe29
Autor:
Florian Posch, Tobias Niedrist, Theresa Glantschnig, Saskia Firla, Florian Moik, Ewald Kolesnik, Markus Wallner, Nicolas Verheyen, Philipp J. Jost, Andreas Zirlik, Martin Pichler, Marija Balic, Peter P. Rainer
Publikováno v:
Frontiers in Cardiovascular Medicine, Vol 9 (2022)
Background/PurposeThis study aims to quantify the utility of monitoring LVEF, hs-cTnT, and NT-proBNP for dynamic cardiotoxicity risk assessment in women with HER2+ early breast cancer undergoing neoadjuvant/adjuvant trastuzumab-based therapy.Material
Externí odkaz:
https://doaj.org/article/9d447758d7e1408a908b0b606cfc1778
Autor:
Cornelia Englisch, Oliver Königsbrügge, Stephan Nopp, Florian Moik, Peter Quehenberger, Matthias Preusser, Ingrid Pabinger, Cihan Ay
Publikováno v:
International Journal of Molecular Sciences, Vol 23, Iss 24, p 15770 (2022)
Venous and arterial thromboembolism (VTE/ATE) are common complications in cancer patients. Antithrombin deficiency is a risk factor for thrombosis in the general population, but its connection to risk of cancer-associated thrombosis is unclear. We in
Externí odkaz:
https://doaj.org/article/0e049d169a974496854472caa1ff44fe
Publikováno v:
Research and Practice in Thrombosis and Haemostasis, Vol 4, Iss 7, Pp 1178-1191 (2020)
Abstract Background Venous thromboembolism (VTE) is frequently observed in patients with coronavirus disease 2019 (COVID‐19). However, reported VTE rates differ substantially. Objectives We aimed at evaluating available data and estimating the prev
Externí odkaz:
https://doaj.org/article/68ad27bedee84adaa577191199fe3893
Publikováno v:
Thrombosis Update, Vol 5, Iss , Pp 100075- (2021)
Patients with cancer are at increased risk of venous thromboembolism (VTE). Risk assessment models can help identifying high-risk populations that might benefit from primary thromboprophylaxis. Currently, the Khorana score is suggested to select pati
Externí odkaz:
https://doaj.org/article/b7f63d62a8a94b4195f5444f8e80f7f5
Publikováno v:
Thrombosis Update, Vol 5, Iss , Pp 100080- (2021)
Cancer patients are at high risk for first and recurrent venous thromboembolism (VTE). While various risk factors for a first cancer-associated VTE event have been identified, information on risk factors for recurrent VTE is limited or inconsistent.
Externí odkaz:
https://doaj.org/article/dcb7aa7850aa41d084d483e9a8a9c188
Publikováno v:
Research and Practice in Thrombosis and Haemostasis, Vol 4, Iss 4, Pp 550-561 (2020)
Abstract Background Low‐molecular‐weight‐heparins (LMWHs) have been established for the treatment of cancer‐associated venous thromboembolism (VTE). Recently published randomized controlled trials (RCTs) have compared direct oral anticoagulan
Externí odkaz:
https://doaj.org/article/78bbbcc5423a49988e6eb275bfd1e4d9
Autor:
Matthias Preusser, Hannah Christina Puhr, Anna Sophie Berghoff, Thorsten Fuereder, Florian Moik, Gerwin Heller, Helmuth Haslacher, Thomas Perkmann, Robert Strassl, Julia Maria Berger, Judith Kreminger, Lorenz Schubert, Angelika Martina Starzer, Ariane Steindl, Stefan Winkler, Selma Tobudic
Publikováno v:
ESMO Open, Vol 5, Iss 5 (2020)
Background During the COVID-19 outbreak, healthcare professionals (HCP) are at the frontline of clinical management and at increased risk for infection. The SARS-CoV-2 seroprevalence of oncological HCP and their patients has significant implications
Externí odkaz:
https://doaj.org/article/6290a4a735ba46fb9069b76abf9e3a7e
Autor:
Matthias Preusser, Hannah Christina Puhr, Anna Sophie Berghoff, Thorsten Fuereder, Florian Moik, Gerwin Heller, Helmuth Haslacher, Thomas Perkmann, Robert Strassl, Julia Maria Berger, Judith Kreminger, Lorenz Schubert, Angelika Martina Starzer, Ariane Steindl, Stefan Winkler, Selma Tobudic
Publikováno v:
ESMO Open, Vol 5, Iss 5 (2020)
Externí odkaz:
https://doaj.org/article/d6b51eefc0f04d66b1b093d051da201e